Panelists discuss how the preliminary results from the IMMagine-1 trial (ASH 2024, abstract #1031) on anitocabtagene autoleucel highlight the evolving role of bispecifics and chimeric antigen receptor (CAR) T-cell therapies in the treatment landscape for relapsed/refractory multiple myeloma (R/R MM).
2 weeks Ago Video content above is prompted by the following: Future of Bispecifics and CAR T in R/R MM: The treatment landscape for R/R MM is evolving, with CAR T therapies and bispecific antibodies emerging as key modalities: Future research will focus on sequencing, combination approaches, and bridging strategies to enhance outcomes and accessibility in R/R MM treatment ..
Gas prices can vary quite a bit from state to state, but one...
